Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03003676
Title A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Targovax Oy
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Maryland Comprehensive Cancer Center Baltimore Maryland United States Details
Memorial Sloan Kettering Cancer Center New York New York United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania United States Details
Oslo University Hospital - The Norwegian Radium Hospital Oslo Norway Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field